Skip to content

This website uses cookies

This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Cookie Policy.

Learn more

.

Order Actinium-225

A Powerful Partner for Commercializing

Actineer has chosen ITM to be the global sales, distribution and customer support service provider. ITM is a founding partner of Actineer and has been leading their global commercial activities for two decades, successfully matching solutions to customer needs.

ITM has built an extensive network of customers, industry partners and research groups. This network will facilitate the commercial availability and efficient global distribution of Actinium-225 .

The commercial distribution of Actinium-225 is led by a team of experts in commercial radionuclide production for nuclear medicine.

Meet Us
.

Alexander Pironi

Executive Vice President, Global Head of Radioisotopes, ITM Group

Alexander Pironi, with his expertise in commercial strategy, is a valuable addition to the Actineer Joint Venture. His proven track record at ITM Isotope Technologies Munich SE, coupled with experience in managing the ITM sales channels and driving sales growth, can significantly benefit the venture.

Moreover, Alexander's background in working with radioisotopes like Lutetium-177 enables him to transfer knowledge effectively to the production and commercialization of Actinium-225, ensuring the venture's success in the dynamic field of nuclear medicine.

.

If you require Actinium-225 or have any sales related questions please contact ITM's sales team. The team is more then happy to answer any questions you might have and advise regarding your intended use of Actinium-225.

ITM is dedicated to facilitate your orders with precision and care, ensuring that you receive the highest quality products and service.

Contact ITM Sales
.

Actineer Quotes

.

Actineer, the joint venture between ITM and CNL, is addressing the growing and urgent global demand for Actinium-225—a rare medical radioisotope that enables the development of innovative therapies for hard-to-treat tumors. By ensuring a stable, scalable supply of this critical resource, Actineer helps to advance both clinical trials and the development of potential life-saving treatments for cancer patients worldwide.
Dr. Andrew Cavey,
CEO of ITM
.

Our joint venture Actineer has been launched with the overall goal to ensure access to Ac-225 as a next generation radioisotope through an innovative technology.
With the foundation of Actineer we have committed us to establish a reliable, long term and substantial production of Ac-225 in high quality standards.
This Canada based company will facilitate ground breaking research activities leading to novel cancer treatments urgently needed by many patients worldwide.
Dr. Andreas Benischke,
VP Global Actinium Lead of ITM
.

It is our role to drive nuclear innovation in Canada, to bring private and public expertise together to spark these new initiatives that will ultimately benefit the health of Canadians and bring new jobs to Canada. We are building on decades of Canada’s world-leading isotope innovation, and have found the key to success is collaboration, partnership, and strong leadership. We are pleased to support the joint venture between CNL and ITM with shared values to bring this potentially lifesaving therapy to the world.
Fred Dermarkar,
President and CEO of AECL
.

Actineer is poised to become one of the major global suppliers of Actinium-225. I am privileged to work with such premier institutions as CNL and ITM and am eager to leverage my expertise and work together with the Actineer team to achieve this goal and thereby support the development of innovative targeted alpha radiopharmaceuticals for the treatment of challenging cancer indications.
Joseph Oliverio,
President and CEO
.

Targeted alpha therapies based on Actinium-225 are gaining increasing importance in addition to the well-established beta emitters such as our highly-pure non-carrier-added (n.c.a.) Lutetium-177. Joining forces with CNL provides us the opportunity to extend our therapeutic portfolio as we continue striving to meet the needs of healthcare professionals and cancer patients worldwide.
Steffen Schuster,
Vice Chairman of the Board of ITM